A detailed history of Stifel Financial Corp transactions in Vaxart, Inc. stock. As of the latest transaction made, Stifel Financial Corp holds 27,490 shares of VXRT stock, worth $14,844. This represents 0.0% of its overall portfolio holdings.

Number of Shares
27,490
Previous 28,690 4.18%
Holding current value
$14,844
Previous $19,000 21.05%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.58 - $0.99 $696 - $1,188
-1,200 Reduced 4.18%
27,490 $23,000
Q2 2024

Aug 13, 2024

SELL
$0.53 - $1.3 $2,120 - $5,200
-4,000 Reduced 12.24%
28,690 $19,000
Q1 2024

May 13, 2024

SELL
$0.56 - $1.41 $56 - $141
-100 Reduced 0.3%
32,690 $42,000
Q3 2023

Nov 13, 2023

BUY
$0.69 - $0.85 $206 - $255
300 Added 0.92%
32,790 $24,000
Q2 2023

Aug 14, 2023

SELL
$0.6 - $1.41 $306 - $719
-510 Reduced 1.55%
32,490 $23,000
Q1 2023

May 12, 2023

SELL
$0.71 - $1.25 $208 - $366
-293 Reduced 0.88%
33,000 $25,000
Q4 2022

Feb 13, 2023

SELL
$0.75 - $2.24 $1,205 - $3,599
-1,607 Reduced 4.6%
33,293 $31,000
Q3 2022

Nov 14, 2022

SELL
$2.09 - $4.5 $3,761 - $8,100
-1,800 Reduced 4.9%
34,900 $76,000
Q2 2022

Aug 15, 2022

BUY
$2.7 - $5.28 $3,375 - $6,600
1,250 Added 3.53%
36,700 $128,000
Q1 2022

May 13, 2022

SELL
$4.29 - $6.64 $3,861 - $5,976
-900 Reduced 2.48%
35,450 $179,000
Q4 2021

Feb 14, 2022

SELL
$5.77 - $7.96 $45,583 - $62,884
-7,900 Reduced 17.85%
36,350 $228,000
Q3 2021

Nov 15, 2021

SELL
$6.67 - $9.8 $16,008 - $23,520
-2,400 Reduced 5.14%
44,250 $352,000
Q2 2021

Aug 13, 2021

BUY
$5.06 - $10.78 $236,048 - $502,886
46,650 New
46,650 $349,000
Q2 2020

Aug 14, 2020

SELL
$1.68 - $8.85 $16,800 - $88,500
-10,000 Closed
0 $0
Q1 2020

May 14, 2020

BUY
$0.34 - $2.87 $3,400 - $28,700
10,000 New
10,000 $18,000

Others Institutions Holding VXRT

About Vaxart, Inc.


  • Ticker VXRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 126,506,000
  • Market Cap $68.3M
  • Description
  • Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1...
More about VXRT
Track This Portfolio

Track Stifel Financial Corp Portfolio

Follow Stifel Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stifel Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Stifel Financial Corp with notifications on news.